Wang YQ, Pan D, Yao ZY, Li YQ, Qu PF, Wang RB, Gu QH, Jiang J, Han ZX, Liu HN. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. World J Gastroenterol 2024; 30(37): 4132-4148 [PMID: 39474397 DOI: 10.3748/wjg.v30.i37.4132]
Corresponding Author of This Article
Hao-Nan Liu, Doctor, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Quanshan District, Xuzhou 221000, Jiangsu Province, China. why974300@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 7, 2024; 30(37): 4132-4148 Published online Oct 7, 2024. doi: 10.3748/wjg.v30.i37.4132
Table 1 Baseline characteristics of the body mass index < 25 kg/m2 and body mass index ≥ 25 kg/m2 groups, n (%)
Variables
BMI < 25 kg/m2 (n = 51)
BMI ≥ 25 kg/m2 (n = 75)
χ2
P value
HBV DNA (IU/mL)
0.31
0.579
HBV > 2000
25 (49.02)
33 (44.00)
HBV ≤ 2000
26 (50.98)
42 (56.00)
HBe
2.05
0.152
Negative
32 (62.75)
56 (74.67)
Positive
19 (37.25)
19 (25.33)
Child-Pugh class
0.52
0.472
A
28 (54.90)
46 (61.33)
B
23 (45.10)
29 (38.67)
PVTT
3.12
0.077
No
26 (50.98)
50 (66.67)
Yes
25 (49.02)
25 (33.33)
BCLC stage
0.30
0.586
B
24 (47.06)
39 (52.00)
C
27 (52.94)
36 (48.00)
Metastasis
0.00
0.979
No
28 (54.90)
41 (54.67)
Yes
23 (45.10)
34 (45.33)
AFP (ng/mL)
3.01
0.083
> 1210
27 (52.94)
28 (37.33)
≤ 1210
24 (47.06)
47 (62.67)
Sex
0.97
0.323
Female
16 (31.37)
30 (40.00)
Male
35 (68.63)
45 (60.00)
Age (years)
1.00
0.316
< 60
26 (50.98)
45 (60.00)
≥ 60
25 (49.02)
30 (40.00)
ECOG
3.49
0.062
0-1
27 (52.94)
52 (69.33)
2
24 (47.06)
23 (30.67)
ALT (U/L)
1.14
0.286
> 40
26 (50.98)
31 (41.33)
≤ 40
25 (49.02)
44 (58.67)
Total bilirubin (μmol/L)
1.29
0.256
> 34
35 (68.63)
44 (58.67)
≤ 34
16 (31.37)
31 (41.33)
Diabetes
0.83
0.361
No
41 (80.39)
55 (73.33)
Yes
10 (19.61)
20 (26.67)
Hypertensive
0.11
0.736
No
15 (29.41)
20 (26.67)
Yes
36 (70.59)
55 (73.33)
Cirrhosis
0.18
0.675
No
28 (54.90)
44 (58.67)
Yes
23 (45.10)
31 (41.33)
Smoking
1.33
0.248
No
31 (60.78)
53 (70.67)
Yes
20 (39.22)
22 (29.33)
Alcohol
0.47
0.491
No
35 (68.63)
47 (62.67)
Yes
16 (31.37)
28 (37.33)
Interventional
0.84
0.358
No
25 (49.02)
43 (57.33)
Yes
26 (50.98)
32 (42.67)
Table 2 Tumor response between body mass index < 25 kg/m2 and body mass index ≥ 25 kg/m2 groups, n (%)
Variables
BMI < 25 kg/m2 (n = 51)
BMI ≥ 25 kg/m2 (n = 75)
χ2
P value
CR
0
51 (100.00)
73 (97.33)
1
0 (0.00)
1 (1.33)
PR
0
48 (94.12)
56 (74.67)
1
3 (5.88)
19 (25.33)
SD
0
34 (66.67)
49 (65.33)
1
17 (33.33)
26 (36.00)
PD
0
20 (39.22)
47 (62.67)
1
31 (60.78)
28 (37.33)
ORR
9.63
0.002
0
48 (94.12)
54 (72.00)
1
3 (5.88)
21 (28.00)
DCR
6.70
0.010
0
31 (60.78)
28 (37.33)
1
20 (39.22)
47 (64.00)
Table 3 Cox subgroup analyses of the prognostic factors for progression-free survival and overall survival based on body mass index
BMI group
HR (95%CI)
Overall survival
18.5-24.9
1 (Reference)
25.0-29.9
0.48 (0.25-0.90)
≥ 30.0
0.28 (0.14-0.57)
P value
0.002
Progression-free survival
18.5-24.9
1 (Reference)
25.0-29.9
0.36 (0.19-0.69)
≥ 30.0
0.13 (0.06-0.31)
P value
< 0.001
Table 4 Univariate and multivariate analyses of the prognostic factors for progression-free survival
Factors
Univariate
Multivariate
HR (95%CI)
P value
HR (95%CI)
P value
AFP (≤ 1210 vs > 1210), ng/mL
1.11 (0.71-1.74)
0.642
-
-
Age (≥ 60 vs < 60), years
1.68 (1.09-2.60)
0.019
1.13 (0.70-1.83)
0.624
Alcohol (yes vs no)
0.94 (0.60-1.46)
0.784
-
-
ALT (> 40 vs ≤ 40), U/L
0.86 (0.56-1.30)
0.468
-
-
BCLC stage (C vs B)
1.85 (1.17-2.93)
0.008
2.60 (1.56-4.33)
< 0.001
BMI (normal vs overweight/obesity)
0.28 (0.15-0.52)
< 0.001
0.32 (0.17-0.59)
< 0.001
Child-Pugh score (B vs C)
2.71 (1.73-4.23)
< 0.001
2.30 (1.44-3.67)
< 0.001
Diabetes (yes vs no)
0.88 (0.53-1.49)
0.644
-
-
Cirrhosis (yes vs no)
0.98 (0.64-1.49)
0.922
-
-
ECOG (2 vs 0-1)
2.37 (1.50-3.72)
< 0.001
2.22 (1.37-3.61)
0.001
HBe (positive vs negative)
1.29 (0.82-2.03)
0.273
-
-
HBV-DNA (HBV ≤ 2000 vs HBV > 2000), IU/mL
1.27 (0.83-1.95)
0.276
-
-
Hypertensive (yes vs no)
1.10 (0.68-1.78)
0.709
-
-
PVTT (yes vs no)
1.06 (0.66-1.67)
0.820
-
-
Metastasis (yes vs no)
0.81 (0.53-1.23)
0.321
-
-
Sex (male vs female)
0.89 (0.58-1.35)
0.576
-
-
Smoking (yes vs no)
1.02 (0.65-1.61)
0.919
-
-
Total bilirubin (≤ 34 vs > 34), μmol/L
0.30 (0.18-0.50)
< 0.001
0.38 (0.21-0.67)
0.001
Interventional (yes vs no)
0.77 (0.48-1.22)
0.263
-
-
Table 5 Univariate and multivariate analyses of the prognostic factors for overall survival
Factors
Univariate
Multivariate
HR (95%CI)
P value
HR (95%CI)
P value
AFP (≤ 1210 vs > 1210), ng/mL
0.59 (0.36-0.95)
0.031
0.42 (0.25-0.72)
0.002
Age (≥ 60 vs < 60), years
0.70 (0.43-1.12)
0.139
-
-
Alcohol (yes vs no)
1.02 (0.64-1.63)
0.932
-
-
ALT (≤ 40 vs > 40), U/L
1.21 (0.77-1.92)
0.409
-
-
BCLC stage (C vs B)
0.59 (0.37-0.94)
0.028
0.43 (0.26-0.70)
0.001
BMI (normal vs overweight/obesity)
0.39 (0.21-0.70)
0.002
0.22 (0.11-0.45)
< 0.001
Child-Pugh score (B vs C)
0.77 (0.48-1.22)
0.266
-
-
Diabetes (yes vs no)
0.92 (0.52-1.60)
0.755
-
-
Cirrhosis (yes vs no)
1.15 (0.72-1.84)
0.562
-
-
ECOG (2 vs 0-1)
0.66 (0.40-1.07)
0.090
-
-
HBe (positive vs negative)
1.09 (0.67-1.78)
0.717
-
-
HBV-DNA (HBV ≤ 2000 vs HBV > 2000), IU/mL
0.67 (0.42-1.07)
0.091
-
-
Hypertensive (yes vs no)
1.20 (0.71-2.05)
0.494
-
-
PVTT (yes vs no)
2.36 (1.35-4.12)
0.003
2.23 (1.26-3.93)
0.006
Metastasis (yes vs no)
0.79 (0.50-1.26)
0.328
-
-
Sex (male vs female)
1.11 (0.70-1.77)
0.658
-
-
Smoking (yes vs no)
1.33 (0.81-2.19)
0.266
-
-
Total bilirubin (≤ 34 vs > 34), μmol/L
1.26 (0.78-2.02)
0.348
-
-
Interventional (yes vs no)
0.75 (0.47-1.19)
0.224
-
-
Table 6 Comparison of training set and validation set features, n (%)
Characteristic
Test (n = 38)
Train (n = 88)
χ2
P value
HBV DNA (IU/mL)
3.06
0.080
HBV > 2000
13 (34.21)
45 (51.14)
HBV ≤ 2000
25 (65.79)
43 (48.86)
HBe
0.38
0.537
Negative
28 (73.68)
60 (68.18)
Positive
10 (26.32)
28 (31.82)
Child-Pugh class
0.27
0.603
A
21 (55.26)
53 (60.23)
B
17 (44.74)
35 (39.77)
PVTT
2.62
0.106
No
27 (71.05)
49 (55.68)
Yes
11 (28.95)
39 (44.32)
BCLC stage
0.00
1.000
B
19 (50.00)
44 (50.00)
C
19 (50.00)
44 (50.00)
Metastasis
0.50
0.480
No
19 (50.00)
50 (56.82)
Yes
19 (50.00)
38 (43.18)
AFP (ng/mL)
0.03
0.872
> 1210
17 (44.74)
38 (43.18)
≤ 1210
21 (55.26)
50 (56.82)
Sex
1.34
0.247
Female
11 (28.95)
35 (39.77)
Male
27 (71.05)
53 (60.23)
BMI
0.02
0.880
≤ 25
15 (39.47)
36 (40.91)
> 25
23 (60.53)
52 (59.09)
Age (years)
1.78
0.182
< 60
18 (47.37)
53 (60.23)
≥ 60
20 (52.63)
35 (39.77)
ECOG
0.54
0.464
0-1
22 (57.89)
57 (64.77)
2
16 (42.11)
31 (35.23)
ALT (U/L)
0.22
0.642
> 40
16 (42.11)
41 (46.59)
≤ 40
22 (57.89)
47 (53.41)
Total bilirubin (μmol/L)
2.81
0.094
> 34
28 (73.68)
51 (57.95)
≤ 34
10 (26.32)
37 (42.05)
Diabetes
3.24
0.072
No
25 (65.79)
71 (80.68)
Yes
13 (34.21)
17 (19.32)
Hypertensive
1.12
0.289
No
13 (34.21)
22 (25.00)
Yes
25 (65.79)
66 (75.00)
Cirrhosis
0.01
0.911
No
22 (57.89)
50 (56.82)
Yes
16 (42.11)
38 (43.18)
Smoking
1.21
0.272
No
28 (73.68)
56 (63.64)
Yes
10 (26.32)
32 (36.36)
Alcohol
0.27
0.605
No
26 (68.42)
56 (63.64)
Yes
12 (31.58)
32 (36.36)
Interventional
0.94
0.332
No
23 (60.53)
45 (51.14)
Yes
15 (39.47)
43 (48.86)
Table 7 Treatment-related adverse events in patients with hepatocellular camrelizumab, n (%)
Variables
BMI < 25 kg/m2 (n = 51)
BMI ≥ 25 kg/m2 (n = 75)
χ2
P value
All grades: Rash
43 (84.31)
56 (74.67)
1.68
0.195
All grades: Nausea
26 (50.98)
30 (40.00)
1.48
0.223
All grades: Diarrhea
13 (25.49)
19 (25.33)
0.00
0.984
All grades: Fatigue
5 (9.80)
20 (26.67)
5.43
0.020
All grades: Myocarditis
3 (5.88)
9 (12.00)
0.70
0.401
All grades: Hyperbilirubinemia
9 (17.65)
10 (13.33)
0.44
0.507
All grades: Hypertension
4 (7.84)
10 (13.33)
0.93
0.336
All grades: Leukopenia
4 (7.84)
10 (13.33)
0.93
0.336
All grades: Thrombocytopenia
7 (13.73)
10 (13.33)
0.00
0.950
All grades: RCCEP
10 (19.61)
11 (14.67)
0.53
0.465
All grades: Neutropenia
4 (7.84)
10 (13.33)
0.93
0.336
All grades: Proteinuria
4 (7.84)
9 (12.00)
0.57
0.451
All grades: Hypothyroidism
5 (9.80)
8 (10.67)
0.02
0.876
All grades: Elevated ALT
6 (11.76)
10 (13.33)
0.07
0.795
All grades: Elevated AST
6 (11.76)
7 (9.33)
0.19
0.660
≥ 3 grades: Rash
5 (9.80)
10 (13.33)
0.36
0.548
≥ 3 grades: Nausea
2 (3.92)
6 (8.00)
0.30
0.583
≥ 3 grades: Diarrhea
0 (0.00)
4 (5.33)
1.34
0.247
≥ 3 grades: Fatigue
3 (5.88)
11 (14.67)
2.37
0.124
≥ 3 grades: Myocarditis
0 (0.00)
3 (4.00)
0.72
0.395
≥ 3 grades: Hyperbilirubinemia
0 (0.00)
3 (4.00)
0.72
0.395
≥ 3 grades: Hypertension
0 (0.00)
1 (1.33)
-
1.000
≥ 3 grades: Leukopenia
0 (0.00)
2 (2.67)
-
0.514
≥ 3 grades: Thrombocytopenia
0 (0.00)
2 (2.67)
-
0.514
≥ 3 grades: RCCEP
1 (1.96)
3 (4.00)
0.02
0.902
≥ 3 grades: Hypothyroidism
1 (1.96)
2 (2.67)
0.00
1.000
≥ 3 grades: Elevated ALT
1 (1.96)
3 (4.00)
0.02
0.902
≥ 3 grades: Elevated AST
3 (5.88)
4 (5.33)
0.00
1.000
≥ 3 grades: Neutropenia
0 (0.00)
0 (0.00)
-
-
≥ 3 grades: Proteinuria
0 (0.00)
0 (0.00)
-
-
Citation: Wang YQ, Pan D, Yao ZY, Li YQ, Qu PF, Wang RB, Gu QH, Jiang J, Han ZX, Liu HN. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. World J Gastroenterol 2024; 30(37): 4132-4148